Evidence that IL-13Rα2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy

Journal of Immunotherapy

Volumn 28, Issue 3, 2005, Pages 193-202

  Kawakami, Koji ^a   Kioi, Mitomu ^a   Liu, Qi ^a   Kawakami, Mariko ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Antisense oligonucleotide; Gene therapy; Glioblastoma; Immunotoxin; Interleukin 13 receptor

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY DNA; CYTOTOXIN; INTERLEUKIN 13; INTERLEUKIN 13 PE38; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER CELL; CANCER SURVIVAL; CANCER THERAPY; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; GENE TRANSFER; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SENSITIVITY ANALYSIS; TUMOR CELL; TUMOR REGRESSION; TUMOR VOLUME;

EID: 17844401189     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000161393.04207.e1     Document Type: Article

References (49)

1. Caput D, Laurent P, Kaghad M, et al. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain. J Biol Chem. 1996;271:16921-16926.
2. Donaldson DD, Whitters MJ, Fitz LJ, et al. The murine IL-13 receptor α2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol. 1998;161:2317-2324.
3. Murata T, Obiri NI, Debinski W, et al. Human ovarian carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J Cancer. 1997;70:230-240.
4. Joshi BH, Plautz GE, Puri RK. IL-13 receptor α chain: a novel tumor associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 2000;60:1168-1172.
5. Husain SR, Puri RK. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood. 2000;95:3506-3513.
6. Liu H, Jacobs BS, Liu J, et al. Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother. 2000;49:319-324.
7. Kawakami K, Kawakami M, Joshi BH, et al. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 2001;61:6194-6200.
8. Kawakami M, Leland P, Kawakami K, et al. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res. 2001;12:459-467.
9. Kawakami M, Kawakami K, Kasperbauer JL, et al. Interleukin-13 receptor α2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res. 2003;9:6381-6388.
10. Kawakami M, Kawakami K, Takahashi S, et al. Analysis of interleukin-13 receptor α2 expression in human pediatric brain tumors. Cancer. 2004;101:1036-1042.
11. Yasunaga S, Yuyama N, Arima K, et al. The negative-feedback regulation of the IL-13 signal by the IL-13 receptor α2 chain in bronchial epithelial cells. Cytokine. 2003;24:293-303.
12. Murata T, Husain SR, Mohri H, et al. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol. 1998;10:1103-1110.
13. Jakubzick C, Choi ES, Joshi BH, et al. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J Immunol. 2003;171:2684-2693.
14. Jakubzick C, Choi ES, Carpenter KJ, et al. Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia. Am J Pathol. 2004;164:1989-2001.
15. Murata T, Obiri NI, Puri RK. Structure of and signal transduction through interleukin 4 and interleukin 13 receptors. Int J Mol Med. 1998;1:551-557.
16. Kelly-Welch AE, Hanson EM, Boothby MR, et al. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003;300:1527-1528.
17. Kawakami K, Taguchi J, Murata T, et al. The interleukin-13 receptor α2 chain: an essential component for binding and internalization but not for IL-13 induced signal transduction through STAT6 pathway. Blood. 2001;97:2673-2679.
18. Murata T, Taguchi J, Puri RK. Interleukin-13 receptor α′ chain but not α chain: a functional component of interleukin-4 receptor. Blood. 1998;91:3884-3891.
19. Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor α2. J Exp Med. 2003;197:703-709.
20. Kawakami K, Takeshita F, Puri RK. Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin-13 binding component IL-13 receptor α2 chain. J Biol Chem. 2001;276:25114-25120.
21. Zhang JG, Hilton DJ, Willson TA, et al. Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned 11-13 receptor and 11-4 receptor alpha-chains. J Biol Chem. 1997;272:9474-9480.
22. Bernard J, Treton D, Vermot-Desroches C, et al. Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Rα2 as a decoy receptor for IL13. Lab Invest. 2001;81:1223-1231.
23. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258-2261.
24. Rahaman SO, Sharma P, Harbor PC, et al. IL-13Rα2, a decoy receptor for IL-13 act as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 2002;62:1103-1109.
25. David MD, Bertoglio J, Pierre J. Functional characterization of IL-13 receptor α2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression. Oncogene. 2003;22:3386-3394.
26. David M, Ford D, Bertoglio J, et al. Induction of the IL-13 receptor α2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways. Oncogene. 2001;20;6660-6668.
27. Kawakami K, Kawakami M, Snoy PJ, et al. in vivo over-expression of IL-13 receptor α2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med. 2001;194:1743-1754.
28. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol. 2000;1:515-520.
29. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 2003;198:1741-1752.
30. Lebel-Binay S, Laguerre B, Quintin-Colonna F, et al. Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol. 1995;25:2340-2348.
31. Ma HL, Whitters MJ, Jacobson BA, et al. Tumor cells secreting IL-13 but not IL-13Rα2 fusion protein have reduced tumorigenicity in vivo. Int Immunol. 2004;16:1009-1017.
32. Debinski W, Obiri NI, Pastan I, et al. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem. 1995;270:16775-16780.
33. Joshi BH, Kawakami K, Leland P, et al. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res. 2002;8:1948-1956.
34. Kioi M, Kawakami K, Puri RK. Analysis of antitumor activity of an IL-13 receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Clin Cancer Res. 2004;10:6231-6238.
35. Puri RK, Leland P, Obiri NI, et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood. 1996;87:4333-4339.
36. Kawakami K, Puri RK. Interleukin-13 and cancer. In: Brombacher F, ed. Interleukin-13. Georgetown, TX: Landes Bioscience, 2003:65-78.
37. Kawakami K, Husain SR, Kawakami M, et al. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol Med. 2002;8:487-492.
38. Husain SR, Joshi BH, Puri RK. Interleulin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer. 2001;92:168-175.
39. Kawakami M, Kawakami K, Puri RK. Intratumoral administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther. 2002;1:999-1007.
40. Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci USA. 1994;91:6889-6893.
41. Kreitman RJ, Puri RK, Pastan I. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res. 1995;55:3357-3363.
42. Templeton NS, Lasic DD, Frederik PM, et al. Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997;15:647-652.
43. Kawakami K, Kawakami M, Husain SR, et al. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor α2 chain in vivo. Gene Ther. 2003;10:1116-1128.
44. Kawakami K, Kawakami M, Puri RK. Interleukin-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer. J Immunol. 2002;169:7119-7126.
45. Kawakami K, Kawakami M, Puri RK. Specifically targeted killing of interleukin-13 receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. Mol Cancer Ther. 2004;3:137-147.
46. Weingart J, Strauss LC, Grossman SA, et al. Phase I/II study: intratumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Neuro-oncol. 2002;4:379.
47. Lang F, Kunwar S, Strauss L, et al. A clinical study of convection-enhanced delivery of IL13-PE38QQR cytotoxin pre- and post-resection of recurrent GBM. 70th annual meeting of the American Association of Neurological Surgeons, Chicago, 2002 (abstract).
48. Ram Z, Barnett G, Vogelbaum M, et al. Pre-operative infusion of IL13-PE38QQR cytotoxin by convection-enhanced delivery (CED) in recurrent malignant glioma: a phase I/II study. American Society of Clinical Oncology annual meeting, 2003 (abstract).
49. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery to macromolecules in the brain. Proc Natl Acad Sci USA. 1994;91:2076-2080.